Lin BioScience, Inc.
6696
Rank in Stocks
#3772
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Share Price
$5.34
Market Cap
$4.43B
Change (1 day)
3.07%
Change (1 year)
-39.48%
Country
TW
Trade Lin BioScience, Inc. (6696)
Category
Healthcare
P/S ratio for Lin BioScience, Inc. (6696)
P/S ratio as of 2026 TTM: 0
According to Lin BioScience, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Lin BioScience, Inc. from 2026 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
